- Aurora Cannabis (ACB) and MedReleaf Australia has launched CraftPlant, a new medical cannabis brand for patients in the Australian market
- The CraftPlant brand includes three new products available for doctors to prescribe – Greendae, Navana and HiVolt
- MedReleaf Australia is a private company which has license to cultivate and manufacture medical cannabis
- Aurora Cannabis cultivates and sells medicinal and recreational cannabis through a portfolio of brands
- Aurora Cannabis Inc. (ACB) is down 0.83 per cent, trading at C$1.19 per share at 12:47 pm ET
Aurora Cannabis (ACB) and MedReleaf Australia have launched CraftPlant, a new medical cannabis brand for patients in the Australian market.
The CraftPlant brand includes three new products available for doctors to prescribe – Greendae, Navana and HiVolt. All three are developed from ultra-premium cultivars and are THC-dominant with high percentages of terpenes.
The cultivars were developed by Occo, Aurora’s leading science and genetics business. The company produces the new range of product under strict EU-GMP certified conditions and will be available in 10g containers.
Miguel Martin, CEO of Aurora Cannabis, commented on the news.
“Through our partnership with MedReleaf Australia, we are proud to continue to lead the way in the Australian market. As we build our strategic international growth plans, Australia proves to be a very promising and sustainable market that we are committed to.”
Aurora currently holds a 10 per cent ownership stake in MedReleaf Australia. Together, they provide Australian patients with several Aurora-branded products, including dried flower, oils and soft gels.
MedReleaf Australia is a private company which has a license to cultivate and manufacture medical cannabis. It also has licences to import, export and wholesale medical cannabis.
Aurora Cannabis cultivates and sells medicinal and recreational cannabis through a portfolio of brands.
Aurora Cannabis Inc. (ACB) is down 0.83 per cent, trading at C$1.19 per share at 12:47 pm ET.